Immunocore (IMCR) 25th Annual Needham Virtual Healthcare Conference summary

Platform overview and differentiation

• T-cell receptor platform enables high-affinity, off-the-shelf soluble TCRs targeting intracellular cancer antigens, accessing over 90% of the proteome.

• Platform addresses immune-cold tumors, infectious diseases, and autoimmune conditions through modularity.

• First TCR therapy approved (KIMMTRAK) for uveal melanoma, demonstrating strong overall survival benefit.

Commercial performance and growth strategy

• KIMMTRAK achieved over $400 million in sales last year and is standard of care in major markets.

• Growth in the US driven by increased therapy duration and deeper community center penetration; OUS growth from new launches and expanded access.

• Real-world duration of therapy now exceeds clinical trial results, reaching about 14 months.

Competitive landscape and future positioning

• New competitor data (darovasertib) addresses HLA-A2 negative population; KIMMTRAK remains standard for HLA-A2 positive.

• Treatment beyond progression is common due to favorable safety and survival benefit.

• Future slotting of new therapies likely after standard of care failure in HLA-A2 positive patients.